Lignocaine kinetics in cardiac patients and aged subjects.

RL Nation, EJ Triggs, M. Selig

Research output: Contribution to journalArticleResearchpeer-review

Abstract

1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half‐lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter‐patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half‐lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4‐hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed. 1977 The British Pharmacological Society

Original languageEnglish
Pages (from-to)439-448
Number of pages10
JournalBritish Journal of Clinical Pharmacology
Volume4
Issue number4
DOIs
Publication statusPublished - 1 Jan 1977

Cite this

@article{67aa5bc833a2456c9170cdb0970aaa61,
title = "Lignocaine kinetics in cardiac patients and aged subjects.",
abstract = "1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half‐lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter‐patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half‐lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4‐hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed. 1977 The British Pharmacological Society",
author = "RL Nation and EJ Triggs and M. Selig",
year = "1977",
month = "1",
day = "1",
doi = "10.1111/j.1365-2125.1977.tb00759.x",
language = "English",
volume = "4",
pages = "439--448",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "4",

}

Lignocaine kinetics in cardiac patients and aged subjects. / Nation, RL; Triggs, EJ; Selig, M.

In: British Journal of Clinical Pharmacology, Vol. 4, No. 4, 01.01.1977, p. 439-448.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Lignocaine kinetics in cardiac patients and aged subjects.

AU - Nation, RL

AU - Triggs, EJ

AU - Selig, M.

PY - 1977/1/1

Y1 - 1977/1/1

N2 - 1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half‐lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter‐patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half‐lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4‐hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed. 1977 The British Pharmacological Society

AB - 1 The pharmacokinetics following long term intravenous infusion of lignocaine to cardiac patients have been examined. 2 Plasma levels and half‐lives of lignocaine and monoethylglycinexylidide (MEGX) showed wide inter‐patient variability. 3 Toxicity reactions to therapy were associated with elevated lignocaine and/or MEGX plasma levels. 4 In a separate study the effect of age on the pharmacokinetics of lignocaine was examined using bolus doses (50 mg) of the drug to young and aged subjects. 5 Elderly subjects had significantly longer half‐lives for lignocaine compared to younger individuals although no change in plasma clearance occurred. 6 The drug appeared to distribute differently in the aged as reflected by significantly increased apparent volumes of distribution. 7 The 24 h urinary recovery of the major metabolite (total 4‐hydroxyxylidine) showed a significant reduction in the elderly when compared to the young. 8 The clinical significance of these studies with respect to lignocaine therapy has been discussed. 1977 The British Pharmacological Society

UR - http://www.scopus.com/inward/record.url?scp=0017713105&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.1977.tb00759.x

DO - 10.1111/j.1365-2125.1977.tb00759.x

M3 - Article

VL - 4

SP - 439

EP - 448

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -